6 results on '"Eickhardt‐Dalbøge, Christina Schjellerup"'
Search Results
2. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
- Author
-
Boklund, Tobias Idor, primary, Snyder, Jordan, additional, Gudmand-Hoeyer, Johanne, additional, Larsen, Morten Kranker, additional, Knudsen, Trine Alma, additional, Eickhardt-Dalbøge, Christina Schjellerup, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Hasselbalch, Hans C., additional, Andersen, Morten, additional, Ottesen, Johnny T., additional, and Stiehl, Thomas, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
- Author
-
Larsen, Morten Kranker, Skov, Vibe, Kjær, Lasse, Eickhardt-Dalbøge, Christina Schjellerup, Knudsen, Trine Alma, Kristiansen, Marie Hvelplund, Sørensen, Anders Lindholm, Wienecke, Troels, Andersen, Morten, Ottesen, Johnny T., Gudmand-Høyer, Johanne, Snyder, Jordan Andrew, Andersen, Mikkel Porsborg, Torp-Pedersen, Christian, Poulsen, Henrik Enghusen, Stiehl, Thomas, Hasselbalch, Hans Carl, Ellervik, Christina, Larsen, Morten Kranker, Skov, Vibe, Kjær, Lasse, Eickhardt-Dalbøge, Christina Schjellerup, Knudsen, Trine Alma, Kristiansen, Marie Hvelplund, Sørensen, Anders Lindholm, Wienecke, Troels, Andersen, Morten, Ottesen, Johnny T., Gudmand-Høyer, Johanne, Snyder, Jordan Andrew, Andersen, Mikkel Porsborg, Torp-Pedersen, Christian, Poulsen, Henrik Enghusen, Stiehl, Thomas, Hasselbalch, Hans Carl, and Ellervik, Christina
- Abstract
The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1–1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03–2.09) for the whole population and 2.93(2.44–3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71–2.69), 2.19(1.89–2.54), and 2.31(1.91–2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10–16), with a HR for NLR ≥ 6 of 2.23(2.17–2.29), 4.10(4.01–4.20), and 7.69(7.50–7.89), for CCI-score 0, 1–2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF., The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10-16), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.
- Published
- 2024
4. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O’Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, Ingham, Anna Cäcilia, Eickhardt-Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O’Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, and Ingham, Anna Cäcilia
- Abstract
Background Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more., Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
- Published
- 2024
5. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
- Author
-
Eickhardt‐Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O' Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, and Ingham, Anna Cäcilia
- Subjects
- *
GUT microbiome , *MYELOPROLIFERATIVE neoplasms , *MYELOFIBROSIS , *POLYCYTHEMIA vera , *NUCLEOTIDE sequencing , *INFECTION control - Abstract
Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady‐state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next‐generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre‐MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub‐diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub‐diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR‐positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F‐positive patients, only minor differences in the gut microbiota were observed between MPN sub‐diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
- Author
-
Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Kristiansen MH, Sørensen AL, Wienecke T, Andersen M, Ottesen JT, Gudmand-Høyer J, Snyder JA, Andersen MP, Torp-Pedersen C, Poulsen HE, Stiehl T, Hasselbalch HC, and Ellervik C
- Subjects
- Humans, Longitudinal Studies, Neutrophils, Lymphocytes, Denmark epidemiology, Myeloproliferative Disorders epidemiology, Polycythemia Vera, Primary Myelofibrosis epidemiology, Thrombocythemia, Essential epidemiology
- Abstract
The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(p
interaction < 2×10-16 ), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.